OPPENHEIMER HOLDINGS INC
No SEC Form 4 filings for $OPY in the last 30 days.
Oppenheimer lowered its price target on Sweetgreen to $8.50 from $10 while keeping an Outperform rating, according to the firm. The note cites ongoing traffic headwinds tied to a cyclospora outbreak, as referenced in related coverage. The change may affect investor expectations for the restaurant chain’s near-term performance.
Oppenheimer raised its price target on JFrog to $115 from $105 and kept an Outperform rating, according to the firm. The article also notes UBS adjusted its target to $120 from $110 while maintaining a Buy rating. Investors may use these changes to gauge revised expectations for JFrog’s stock.
Oppenheimer raised its Booking Holdings price target to $240 from $215 and kept an Outperform rating, according to the firm. The note cites its composite rating methodology based on valuation, EPS revisions, and visibility. The update may affect investor expectations for Booking’s near-term outlook.
Over the past 7 days, alphai's AI scored 1 news story mentioning OPY (OPPENHEIMER HOLDINGS INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent OPY coverage spans financial news and earnings.
Oppenheimer lowered its price target on Sweetgreen to $8.50 from $10 while keeping an Outperform rating, according to the firm. The note cites ongoing traffic headwinds tied to a cyclospora outbreak, as referenced in related coverage. The change may affect investor expectations for the restaurant chain’s near-term performance.
Oppenheimer raised its price target on JFrog to $115 from $105 and kept an Outperform rating, according to the firm. The article also notes UBS adjusted its target to $120 from $110 while maintaining a Buy rating. Investors may use these changes to gauge revised expectations for JFrog’s stock.
Oppenheimer raised its Booking Holdings price target to $240 from $215 and kept an Outperform rating, according to the firm. The note cites its composite rating methodology based on valuation, EPS revisions, and visibility. The update may affect investor expectations for Booking’s near-term outlook.
Oppenheimer cut its Harmony Biosciences (NASDAQ:HRMY) price target to $70 from $85 but kept an Outperform rating after model updates. Harmony reported Q2 2026 Wakix net sales of $261.3M (+30% YoY) and reaffirmed full-year guidance of $1.00B to $1.04B. Oppenheimer cited new Phase 1 data for BP-205 and expects further Phase 1 readouts in Q4 2026 and early 2027.
Oppenheimer lowered its price target on Fidelity National Information Services (FIS) to $54 from $62, according to the firm. The article also notes other analysts cut targets, including Baird to $48 from $54 and Susquehanna to $46 from $55. The stock closed at $44.26, down 1.16%.
alphai scores every news story that mentions OPY with an AI model for sentiment and relevance, and aggregates insider trades from OPPENHEIMER HOLDINGS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Oppenheimer lowered its price target on Sweetgreen to $8.50 from $10 while keeping an Outperform rating, according to the firm. The note cites ongoing traffic headwinds tied to a cyclospora outbreak, as referenced in related coverage. The change may affect investor expectations for the restaurant chain’s near-term performance.
2 min readOppenheimer raised its price target on JFrog to $115 from $105 and kept an Outperform rating, according to the firm. The article also notes UBS adjusted its target to $120 from $110 while maintaining a Buy rating. Investors may use these changes to gauge revised expectations for JFrog’s stock.
2 min readOppenheimer raised its Booking Holdings price target to $240 from $215 and kept an Outperform rating, according to the firm. The note cites its composite rating methodology based on valuation, EPS revisions, and visibility. The update may affect investor expectations for Booking’s near-term outlook.
1 min readOppenheimer cut its Harmony Biosciences (NASDAQ:HRMY) price target to $70 from $85 but kept an Outperform rating after model updates. Harmony reported Q2 2026 Wakix net sales of $261.3M (+30% YoY) and reaffirmed full-year guidance of $1.00B to $1.04B. Oppenheimer cited new Phase 1 data for BP-205 and expects further Phase 1 readouts in Q4 2026 and early 2027.
4 min readOppenheimer lowered its price target on Fidelity National Information Services (FIS) to $54 from $62, according to the firm. The article also notes other analysts cut targets, including Baird to $48 from $54 and Susquehanna to $46 from $55. The stock closed at $44.26, down 1.16%.
2 min readOppenheimer raised its Backblaze price target to $25 from $15 and kept an Outperform rating, according to the firm. B. Riley also adjusted its Backblaze target to $24 from $16 while maintaining a Buy rating. The changes may affect investor expectations for the stock.
1 min readSimply Wall St reports Oppenheimer Holdings (OPY) shares fell 3.7% to $106.64 after results. It cites Q1 2026 revenue of $426.4m versus $346.4m a year earlier, but net income swung to a $20.6m loss from a $30.7m profit, with basic EPS turning to -$1.93 from $2.93. The article notes trailing 12-month net income rose to $97.2m.
3 min readOppenheimer raised its price target on EMCOR Group to $1,200 from $1,100 and kept an Outperform rating, according to the firm. The article also notes UBS adjusted its EMCOR target to $1,065 from $975 with a Buy rating. These changes may affect investor expectations for EMCOR’s shares.
1 min readOppenheimer cut its price target on Coinbase Global to $193 from $209 while keeping an Outperform rating, according to the firm. The article also notes other broker target changes on July 31, including JPMorgan to $148 from $196 and Mizuho to $155 from $200.
1 min readOppenheimer Holdings (NYSE: OPY) reported Q2 2026 net income of $27.4M, or $2.55 basic EPS, up from $21.7M, or $2.06 EPS, a year earlier. Revenue rose 21.9% to $454.9M. Adjusted net income was $45.7M, or $4.27 EPS, after excluding a $24.9M pre-tax stock-price-linked compensation expense.
7 min read
